Holen Sie sich die Stockscreener-App
1.505
5.24%
0.075
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Liontrust Investment Partners Discloses Investment at MaxCyte with 5.03% Stake - TradingView
MaxCyte MXCT Hires Danaher Dealmaker To Drive Growth - StocksToTrade
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Zacks Investment Research
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
MaxCyte (MXCT) Stock Analysis Report | Financials & Insights - Benzinga España
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. - Stock Titan
MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - ad-hoc-news.de
MXCT stock holds steady as MaxCyte prepares next growth steps - ad-hoc-news.de
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.42%Share Dilution Risk - vinanet.vn
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT) - The Globe and Mail
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com India
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com UK
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - vinanet.vn
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - dars.gov.et
MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks - Finimize
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Nigeria
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - vinanet.vn
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - dars.gov.et
MaxCyte launches base editor off-target nomination assays - Investing.com
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Canada
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com India
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - The Manila Times
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - marketscreener.com
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04%Earnings Sentiment Score - vinanet.vn
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
MaxCyte, Inc. Releases Q2 2026 Results: Cell Engineering Platform Momentum in FocusRevenue Inflection Point - dars.gov.et
MaxCyte (MXCT) Earnings Call Q2 2026: Prognose bekräftigt bei Ausbau der Genentech-Partnerschaft - TradingKey
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - medicalbuyer.co.in
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte Q2 Earnings Call Highlights - Yahoo Finance
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
0.51%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):